title: Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection.
abstract: OBJECTIVE
  The objective of this study was to assess clinical outcomes and fertility in patients treated conservatively for unilateral stage I invasive epithelial ovarian cancer (EOC).
  
  
  METHODS
  A multi-institutional retrospective investigation was undertaken to identify patients with unilateral stage I EOC treated with fertility-sparing surgery. Favorable histology was defined as grade 1 or grade 2 adenocarcinoma, excluding clear cell histology.
  
  
  RESULTS
  A total of 211 patients (stage IA, n = 126; stage IC, n = 85) were identified from 30 institutions. Median duration of follow-up was 78 months. Five-year overall survival and recurrence-free survival were 100% [corrected] and 97.8% for stage IA and favorable histology (n = 108), 100% and 100% for stage IA and clear cell histology (n = 15), 100% and 33.3% for stage IA and grade 3 (n = 3), 96.9% and 92.1% for stage IC and favorable histology (n = 67), 93.3% and 66.0% for stage IC and clear cell histology (n = 15), and 66.7% and 66.7% for stage IC and grade 3 (n = 3). Forty-five (53.6%) of 84 patients who were nulliparous at fertility-sparing surgery and married at the time of investigation gave birth to 56 healthy children.
  
  
  CONCLUSIONS
  Our data confirm that fertility-sparing surgery is a safe treatment for stage IA patients with favorable histology and suggest that stage IA patients with clear cell histology and stage IC patients with favorable histology can be candidates for fertility-sparing surgery followed by adjuvant chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575, Japan. toyomi-s@md.tsukuba.ac.jp
authors.forename: Toyomi
authors.initials: T
authors.lastname: Satoh
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hatae
authors.forename: Yoh
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Nobuo
authors.initials: N
authors.lastname: Yaegashi
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishiko
authors.forename: Shoji
authors.initials: S
authors.lastname: Kodama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ochiai
authors.forename: Masashi
authors.initials: M
authors.lastname: Takano
authors.forename: Harushige
authors.initials: H
authors.lastname: Yokota
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Sadako
authors.initials: S
authors.lastname: Nishimura
authors.forename: Daiki
authors.initials: D
authors.lastname: Ogishima
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Tanri
authors.initials: T
authors.lastname: Shiozawa
authors.forename: Toru
authors.initials: T
authors.lastname: Nakanishi
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Kamura
authors.forename: Ikuo
authors.initials: I
authors.lastname: Konishi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yoshikawa
mesh_terms: D000293:Adolescent; D000328:Adult; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D018579:Patient Selection; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome